{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"15.1","upperLimit":"40.4","value":"31.8"},{"groupId":"OG001","lowerLimit":"11.1","upperLimit":"47.9","value":"22.6"},{"groupId":"OG002","lowerLimit":"9.4","upperLimit":"21.7","value":"13.4"},{"groupId":"OG003","lowerLimit":"15.1","upperLimit":"34.8","value":"21.7"},{"comment":"The upper limit of 95% CI was not estimable due to insufficient number of participants with events.","groupId":"OG004","lowerLimit":"36.8","upperLimit":"NA","value":"51.8"},{"comment":"The median and upper limit of 95% CI was not estimable due to insufficient number of participants with events.","groupId":"OG005","lowerLimit":"12.9","upperLimit":"NA","value":"NA"},{"groupId":"OG006","lowerLimit":"5.5","upperLimit":"25.1","value":"11.1"},{"comment":"The median and upper limit of 95% CI was not estimable due to insufficient number of participants with events.","groupId":"OG007","lowerLimit":"6.0","upperLimit":"NA","value":"NA"},{"comment":"The 95% CI was not estimable due to insufficient number of participants with events.","groupId":"OG008","lowerLimit":"NA","upperLimit":"NA","value":"5.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"83"},{"groupId":"OG003","value":"34"},{"groupId":"OG004","value":"56"},{"groupId":"OG005","value":"23"},{"groupId":"OG006","value":"13"},{"groupId":"OG007","value":"4"},{"groupId":"OG008","value":"1"}],"units":"Participants"}],"description":"DOR was defined as the time from first documented response (CR/PR) to the date of first documented PD or death due to any cause, whichever occurs first. CR was defined as the disappearance of all target lesions or any pathological lymph nodes (whether target or non-target) having a reduction in the short axis to \\<10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. PD was defined as at least a 20% increase in SOD of target lesions, taking as reference the smallest SOD on study (including baseline). DOR was analyzed using the KM methods.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants who had RET-fusion positive NSCLC previously treated with platinum-based chemotherapies received pralsetinib, 400 mg orally, QD until discontinuation due to toxicity, disease progression, or other reasons.","id":"OG000","title":"RET- Fusion Positive NSCLC With Prior Platinum Treatment"},{"description":"Participants who had RET-fusion positive NSCLC previously treated with non-platinum or systemic therapies received pralsetinib, 400 mg orally, QD until discontinuation due to toxicity, disease progression, or other reasons.","id":"OG001","title":"RET-fusion Positive NSCLC With Non-platinum Systemic Treatment"},{"description":"Participants who had RET-fusion positive NSCLC not previously treated with systemic or platinum-based chemotherapies received pralsetinib, 400 mg orally, QD until discontinuation due to toxicity, disease progression, or other reasons.","id":"OG002","title":"RET-fusion Positive NSCLC With No Prior Systemic or Platinum Treatment"},{"description":"Participants who had RET- mutation positive MTC previously treated with either cabozantinib and/or vandetanib therapies received pralsetinib, 400 mg orally, QD until discontinuation due to toxicity, disease progression, or other reasons.","id":"OG003","title":"RET-mutation MTC With Prior Cabozantinib and/or Vandetanib Treatment"},{"description":"Participants who had RET- mutation positive MTC not previously treated with cabozantinib or vandetanib therapies received pralsetinib, 400 mg orally, QD until discontinuation due to toxicity, disease progression, or other reasons.","id":"OG004","title":"RET-mutation MTC With No Prior Cabozantinib or Vandetanib Treatment"},{"description":"Participants who had RET-fusion positive TC received pralsetinib, 400 mg, orally, QD until discontinuation due to toxicity, disease progression, or other reasons.","id":"OG005","title":"RET-fusion Positive TC"},{"description":"Participants who had other RET-positive solid tumors other than NSCLC and TC received pralsetinib, 400 mg, orally, QD until discontinuation due to toxicity, disease progression, or other reasons.","id":"OG006","title":"RET-fusion Positive Solid Tumors Other Than NSCLC and TC"},{"description":"Participants who had RET-altered (fusion or mutation) solid tumors previously treated with a selective RET TKI received pralsetinib, 400 mg, orally, QD until discontinuation due to toxicity, disease progression, or other reasons.","id":"OG007","title":"RET-altered Solid Tumors Previously Treated With RET Inhibitor"},{"description":"Participants who had RET-mutation positive solid tumors received pralsetinib, 400 mg, orally, QD until discontinuation due to toxicity, disease progression, or other reasons.","id":"OG008","title":"RET-mutation Positive Tumors Other Than MTC"}],"paramType":"MEDIAN","populationDescription":"RET-altered measurable disease population included participants in the efficacy population who have measurable (target) disease per RECIST v1.1, at baseline according to BICR \\& sufficient evidence of a RET alteration. As prespecified in SAP, Phase 1 participants treated at 400 mg QD are pooled with Phase 2 participants for efficacy analysis. Participants who had a response of CR/PR were analyzed in this OM.","reportingStatus":"POSTED","timeFrame":"Up to approximately 79.8 months","title":"Phase 2: DOR","type":"SECONDARY","unitOfMeasure":"months"}